RIGEL PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 5.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-03
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 5.90%, a 7.81% decline from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 6.40%.
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -5.30%, a 312.00% decline from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 2.50%, a 55.36% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 5.90% 10-K · filed 2026-03-03 | |
| 2024-12-31 | 6.40% 10-K · filed 2026-03-03 | |
| 2023-12-31 | -5.30% 10-K · filed 2026-03-03 | 5.30% 10-K · filed 2024-03-05 |
| 2022-12-31 | 2.50% 10-K · filed 2025-03-04 | |
| 2021-12-31 | 5.60% 10-K · filed 2024-03-05 | |
| 2020-12-31 | 4.70% 10-K · filed 2023-03-07 | |
| 2019-12-31 | 2.80% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 8.20% 10-K · filed 2021-03-02 | |
| 2017-12-31 | 5.70% 10-K · filed 2020-02-27 | |
| 2016-12-31 | 5.00% 10-K · filed 2019-02-28 | |
| 2015-12-31 | 8.30% 10-K · filed 2018-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |